Hydroxyflavone-Modified Aza-BODIPY Derivatives for Photodynamic and CO Therapy

Supapon Kwangmettatam developed hydroxyflavone-modified aza-BODIPY derivatives as metal-free photosensitizers for neuroblastoma treatment. The dataset, last updated on May 13, 2026, likely contains experimental results for compounds integrating photodynamic therapy with singlet oxygen-triggered carbon monoxide release. It includes data on near-infrared absorption, singlet oxygen generation, and phototherapeutic activity under hypoxic and normoxic conditions.

Use Cases

• Compare phototherapeutic activity of different aza-BODIPY derivatives based on the described compound series.
• Analyze the relationship between singlet oxygen generation efficiency and phototoxicity based on the described mechanism.
• Investigate the impact of localized carbon monoxide release on oxidative stress-induced apoptosis based on the described sensitizing component.
• Assess potential for extracranial neuroblastoma application based on the described zebrafish biodistribution studies.

Strengths

• Data describes a specific, novel molecular framework (hydroxyflavone-modified aza-BODIPY) for combination therapy.
• Mechanistic studies are included, indicating primary cytotoxic pathways and sensitizing components.
• Experimental results include performance under hypoxic conditions, a relevant tumor microenvironment factor.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is very small at 2.2 KB, indicating limited scope.

Provenance

Source

figshare

Collection Method

Likely contains synthesized experimental data from the described research.

Freshness

Last updated 2026-05-13 18:03:33; freshness should be verified.